A group of experts suggests that the use of mRNA COVID-19 vaccines should be considered as preferable in the US rather than the Johnson & Johnson (J&J) COVID-19 vaccine for women below 50 years of age.

The recommendation has been made in an editorial in JAMA published online April 30, which accompanies a paper that details 12 case reports of cerebral venous sinus thrombosis (CVST) with thrombocytopenia after administration of the J&J COVID-19 vaccine (Ad26.COV2.S vaccine).

The US case reports of 12 patients, 3 of which were fatal, had several similarities to the cases described in Europe following the AstraZeneca vaccine. By April 12, around 7 million doses of the J&J vaccine had been given in the US. Twelve cases of CVST and thrombocytopenia after administration of the vaccine were reported to VAERS from March 2 through April 21. All of these cases were in white women, 11 being in those under 50 years of age… (Medscape)